Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by SouthernTierTomon Mar 24, 2022 1:06pm
147 Views
Post# 34542081

RE: The "Exhumation of Eden" - Yeah, should have been an NR

RE: The "Exhumation of Eden" - Yeah, should have been an NR I would have NR'd the start of Eden, but that is just me....

Here is the detail of Eden "buried within the MD&A..I'm quite certain ALL retailers read the "MD&A" don't they? ; - )

Bear in mind, they pulled the same move when the arrangement with Toray on the 5yr extstension of the PMX deal was done.  They "MD&A'd it"..but close to ONE year after it's completion.

Here is the "SUB-trial" just launched, nice cuz it could ramp up TIGRIS numbers without the public being aware.  I'm still waiting for the Covid Trial results to be shared.  Sending out the recording of the complicit professor chatting with the former pot exec doesn't count "Donnie" ; - )

In March 2022, the Company launched an ancillary observational study, EDEN, to collect data on patients with sepsis even if ineligible for Tigris. EDEN will capture much needed data on the full range of septic shock and its relation to organ failure and endotoxin activity. These data will inform subsequent discussions with the FDA on labelling for PMX as well as to provide the medical community and the Company a better picture of the addressable population in the U.S. for PMX. Furthermore, patients enrolled in EDEN will also be considered for entry into Tigris study, which provides another tool to support enrollment.
<< Previous
Bullboard Posts
Next >>